Shi PY, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Preprint. Res Sq. 2021;rs.3.rs-143532. doi:10.21203/rs.3.rs-143532/v1
Xie X, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. Preprint. bioRxiv. 2021;2021.01.07.425740. doi:10.1101/2021.01.07.425740ファイザー/BioNTech テキサス大学のグループによる有効性の確認
Muik A, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. Science. 2021;eabg6105. doi:10.1126/science.abg6105
Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines. Preprint. bioRxiv. 2021;2021.01.27.428516. doi:10.1101/2021.01.27.428516
Ho D, et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. Preprint. Res Sq. 2021;rs.3.rs-155394. doi:10.21203/rs.3.rs-155394/v1
Wang P, et al. Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization. Preprint. bioRxiv. 2021;2021.01.25.428137. doi:10.1101/2021.01.25.428137
Jangra S, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. Preprint. medRxiv. 2021;2021.01.26.21250543. doi:10.1101/2021.01.26.21250543
Logunov DY, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. DOI:https://doi.org/10.1016/S0140-6736(21)00234-8
Dai Y, et al. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines. Sci Bull (Beijing). 2021;10.1016/j.scib.2021.01.005. doi:10.1016/j.scib.2021.01.005 中国科学院と中国国家自然科学財団が共同出版するジャーナル
Li Y, et al. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification. J Ethnopharmacol. 2021;271:113854. doi:10.1016/j.jep.2021.113854
Xiong H, et al. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools. Eur J Integr Med. 2020;40:101241. doi:10.1016/j.eujim.2020.101241
Zhu YW, et al. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods. J Tradit Complement Med. 2021;10.1016/j.jtcme.2021.01.004. doi:10.1016/j.jtcme.2021.01.004
Ceccarelli G, et al. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study. Front Nutr. 2021;7:613928. doi:10.3389/fnut.2020.613928
Schultz IC, et al. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis. Stem Cell Rev Rep. 2021;1-16. doi:10.1007/s12015-021-10122-0
Okoye NC, et al. Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting. J Clin Microbiol. 2021;JCM.03282-20. doi:10.1128/JCM.03282-20
アボットBinaxNOWCOVID-19抗原検査キットの評価
無症候ユタ大学生2645人
RT-PCR陽性者: 1.7% (45/2645)
BinaxNOW: 24/RT-PCR陽性者45, 感度53.3%, 特異度100%
RT-PCR陽性かつBinaxNOW陽性のCt値は、RT-PCR陽性かつBinaxNOW陰性と比較して有意に低い (17.6 vs 29.6)
Landoni G, et al. Nations with high smoking rate have low SARS-CoV-2 infection and low COVID-19 mortality rate. Acta Biomed. 2020;91(4):e2020168. doi:10.23750/abm.v91i4.10721
COVID-19の死亡率 男性喫煙者>45%の国: 13/100万人 vs. 男性喫煙者<25%未満の国: 33/100万人
SARS-CoV-2感染率 男性喫煙者>45%の国: 436/100万人 vs. 男性喫煙者<25%未満の国: 1139/100万人
能動喫煙はCOVID-19に対して保護的
Marouf N, et al. Association between periodontitis and severity of COVID-19 infection: a case-control study. J Clin Periodontol. 2021;10.1111/jcpe.13435. doi:10.1111/jcpe.13435
Asher A, et al. Blood omega-3 fatty acids and death from COVID-19: A pilot study [published online ahead of print, 2021 Jan 20]. Prostaglandins Leukot Essent Fatty Acids. 2021;166:102250. doi:10.1016/j.plefa.2021.102250